Clinical Trial Update: A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating TAK-981 plus rituximab in adults with relapsed or refractory CD20-positive non-Hodgkin lymphoma was terminated, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• TAK-981

Snippet

Sponsor: Takeda | Conditions: Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-14